ストックスクリーナーアプリを入手
32.20
0.44%
0.14
アフターアワーズ：
32.23
0.03
+0.09%
前日終値:
$32.06
開ける：
$32.19
24時間の取引高:
6.01M
Relative Volume:
0.57
時価総額：
$12.45B
収益：
$3.14B
当期純損益:
$-3.36B
株価収益率:
-3.6884
EPS:
-8.73
ネットキャッシュフロー:
$-4.03B
1週間 パフォーマンス:
-6.07%
1か月 パフォーマンス:
+26.03%
6か月 パフォーマンス:
-5.46%
1年 パフォーマンス:
-74.04%
1日の値動き範囲:
$31.97
$32.72
1週間の範囲:
$31.42
$34.07
52週間の値動き範囲:
$23.15
$126.42
Moderna Inc Stock (MRNA) Company Profile
MRNA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
32.20 | 13.26B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-13 | 開始されました | Citigroup | Neutral |
| 2025-02-18 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2025-01-29 | ダウングレード | Goldman | Buy → Neutral |
| 2024-12-18 | ダウングレード | Argus | Buy → Hold |
| 2024-12-10 | 再開されました | BofA Securities | Underperform |
| 2024-11-19 | 開始されました | Berenberg | Hold |
| 2024-11-18 | アップグレード | HSBC Securities | Hold → Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Underperform |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-09-13 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2024-09-13 | ダウングレード | Jefferies | Buy → Hold |
| 2024-09-13 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-08-28 | アップグレード | HSBC Securities | Reduce → Hold |
| 2024-08-07 | アップグレード | Deutsche Bank | Sell → Hold |
| 2024-08-05 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | ダウングレード | HSBC Securities | Hold → Reduce |
| 2024-01-02 | アップグレード | Oppenheimer | Perform → Outperform |
| 2023-11-29 | 開始されました | Canaccord Genuity | Hold |
| 2023-11-03 | アップグレード | HSBC Securities | Reduce → Hold |
| 2023-11-02 | ダウングレード | Deutsche Bank | Hold → Sell |
| 2023-08-04 | ダウングレード | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2023-07-24 | 開始されました | William Blair | Mkt Perform |
| 2023-07-14 | 開始されました | HSBC Securities | Reduce |
| 2023-06-26 | アップグレード | UBS | Neutral → Buy |
| 2023-04-26 | 開始されました | Guggenheim | Neutral |
| 2023-03-13 | アップグレード | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-02-24 | ダウングレード | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | アップグレード | Jefferies | Hold → Buy |
| 2022-12-14 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | アップグレード | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | アップグレード | Deutsche Bank | Hold → Buy |
| 2022-02-01 | アップグレード | Redburn | Sell → Neutral |
| 2022-01-26 | アップグレード | Deutsche Bank | Sell → Hold |
| 2022-01-21 | アップグレード | BofA Securities | Underperform → Neutral |
| 2022-01-21 | 開始されました | UBS | Neutral |
| 2021-12-07 | 開始されました | Cowen | Market Perform |
| 2021-11-09 | 開始されました | Wolfe Research | Outperform |
| 2021-10-22 | 開始されました | Deutsche Bank | Sell |
| 2021-10-15 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2021-08-06 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | 繰り返されました | Jefferies | Hold |
| 2021-02-01 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2020-12-16 | ダウングレード | Jefferies | Buy → Hold |
| 2020-12-16 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | ダウングレード | Needham | Buy → Hold |
| 2020-11-23 | 開始されました | Wells Fargo | Equal Weight |
| 2020-11-17 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2020-07-20 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-07-13 | 開始されました | Jefferies | Buy |
| 2020-06-30 | 開始されました | Argus | Buy |
| 2020-06-08 | 開始されました | Barclays | Overweight |
| 2020-04-30 | 開始されました | BMO Capital Markets | Outperform |
| 2020-03-05 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | 再開されました | BofA/Merrill | Buy |
| 2019-10-25 | 開始されました | ROTH Capital | Buy |
| 2019-04-05 | 開始されました | Chardan Capital Markets | Buy |
すべてを表示
Moderna Inc (MRNA) 最新ニュース
Lobbying Update: $120,000 of MODERNA INC. lobbying was just disclosed - Quiver Quantitative
Moderna to Report Second Quarter 2025 Financial Results on Friday, August 1, 2025 - Amarillo Globe-News
IBM-Moderna Showcase Quantum-Enhanced Drug Discovery - HPCwire
Nisa Investment Advisors LLC Purchases 21,330 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
IBM and Moderna Team Up on Quantum Study. What It Means for the World of Medicine. - Barron's
Director, Strategic Forecasting, Oncology job with Moderna, Inc. | 1402245670 - New Scientist
Moderna’s latest approval again reveals FDA rift over COVID vaccines - BioPharma Dive
OVERSEA CHINESE BANKING Corp Ltd Purchases 17,268 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
William Blair Issues Negative Outlook for Moderna Earnings - MarketBeat
Cwm LLC Acquires 28,831 Shares of Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
FDA Fully Approves Moderna’s COVID-19 Vaccine for Some Young Children - Vaccine Advisor
Lobbying Update: $100,000 of MODERNA US INC. lobbying was just disclosed - Quiver Quantitative
Moderna gets full FDA approval for kids COVID-19 vaccine - MSN
Moderna patent for mRNA vaccine knocked back, for now - Lawyerly
Moderna: Ready For The Redemption Arc (NASDAQ:MRNA) - Seeking Alpha
Reflecting On Therapeutics Stocks’ Q1 Earnings: Moderna (NASDAQ:MRNA) - Yahoo Finance
Opinion: It's Time to Load Up on This Biotech Giant After Its 80% Crash - Yahoo Finance
Opinion: It's Time to Load Up on This Biotech Giant After Its 80% Crash - The Motley Fool
Bank of New York Mellon Corp Has $54.38 Million Stock Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Why Moderna (MRNA) Stock Is Falling Today - Yahoo Finance
FDA Accepts GSK Filing for Expanded Use of RSV Shot in Younger Adults - The Globe and Mail
Class Action Filed Against Moderna, Inc. (MRNA) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
What to Expect From Moderna's Next Quarterly Earnings Report - MSN
What To Expect From Moderna's Next Quarterly Earnings Report - Barchart.com
Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Teacher Retirement System of Texas - MarketBeat
Financial Gravity Asset Management Inc. Invests $1.28 Million in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Lobbying Update: $20,000 of MODERNA INC. lobbying was just disclosed - Nasdaq
Trend Tracker for (MRNA) - news.stocktradersdaily.com
Top Large Cap Stock Gainers Last WeekModerna (NASDAQ:MRNA), Coinbase Global (NASDAQ:COIN), Delta Air Lines (NYSE:DAL) - Benzinga
Moderna, Inc. (NASDAQ:MRNA) Stock Holdings Raised by Moloney Securities Asset Management LLC - MarketBeat
Moderna (NasdaqGS:MRNA) Added to Russell Midcap Indexes - Yahoo Finance
Moderna (MRNA) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance
FDA approves Moderna COVID-19 vaccine for high-risk children - TechTarget
U.S. Physical Therapy, Evolent Health, Charles River Laboratories, Moderna, and Intuitive Surgical Shares Are Falling, What You Need To Know - FinancialContent
FDA approves Moderna's COVID vaccine for children as young as 6 months old - Scripps News
Moderna COVID shot gets FDA approval for kids 6 months to 11 years - USA Today
MRNA Stock Up on Full FDA Nod for COVID-19 Jab in Pediatric Patients - Yahoo Finance
Moderna Wins Full Approval for COVID-19 Shot for Higher-Risk Kids - BioSpace
Moderna (NASDAQ:MRNA) Shares Up 8.4%Here's What Happened - MarketBeat
Moderna’s COVID vaccine gets full US approval for at-risk children aged 6 months and older - MSN
Moderna Receives Full U.S. FDA Approval for COVID-19 Vaccine, Spikevax, in Children Aged 6 Months Through 11 Years at Increased Risk for COVID-19 Disease - Great Falls Tribune
FDA gives full approval to Moderna COVID shot for at-risk kids - The Hill
Moderna stock rises after FDA approves COVID-19 vaccine for at-risk children - Investing.com Nigeria
Pfizer Takes Aim At Moderna's Leftover MRNA Protections - Law360
Moderna COVID shot for kids cleared in face of RFK Jr. criticism - The Boston Globe
FDA Grants Complete Approval To Moderna's COVID-19 Vaccine For Children As Young As 6 Months - Benzinga
FDA grants full approval to Moderna’s Covid vaccine for children but limits eligibility - STAT
Moderna gets full US approval for COVID shot in at-risk children 6 months and older - Reuters
Moderna COVID vaccine gets full approval for children - BioPharma Dive
Why Moderna (MRNA) Stock Is Up Today - Yahoo Finance
Moderna Stock Has Risen 19% This Month. Is It Now A Buy? - Investor's Business Daily
Moderna Inc (MRNA) 財務データ
収益
当期純利益
現金流量
EPS
0.64%
0.37%
大文字化:
|
ボリューム (24 時間):